BRIEF-Sanofi: EU Approves Sarclisa As 1st Anti-CD38 Therapy For Newly Diagnosed Multiple Myeloma

Jan 22 (Reuters) - Sanofi SA SASY.PA:

• SARCLISA APPROVED IN THE EU AS THE FIRST ANTI-CD38 THERAPY IN COMBINATION WITH STANDARD-OF-CARE VRD TO TREAT TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

• EU APPROVES SARCLISA AS FIRST ANTI-CD38 THERAPY FOR NDMM

• APPROVAL BASED ON POSITIVE IMROZ PHASE 3 STUDY RESULTS

• SARCLISA REGULATORY SUBMISSIONS UNDER REVIEW IN JAPAN AND CHINA

• REPRESENTS THIRD INDICATION IN EU, INCLUDING TWO FOR TREATMENT OF ADULT PATIENTS WITH R/R MM, AND ONE IN NDMM

• WITH TODAY'S DECISION 27 COUNTRIES IN EU WILL HAVE ACCESS TO A POTENTIALLY TRANSFORMATIVE NEW COMBINATION REGIMEN

Source text: ID:nGNX2RwYFw

Further company coverage: SASY.PA

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))